FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226153130> ?p ?o ?g. }

• W4226153130 endingPage "e2131" @default.
• W4226153130 startingPage "e2120" @default.
• W4226153130 abstract "Background and Objectives To investigate the potential of plasma neurofilament light (pNfL) as a biomarker of disease progression and treatment response in progressive multiple sclerosis (PMS) with and without acute disease activity. Methods A post hoc blinded analysis of pNfL levels in 2 placebo-controlled, phase 3 studies in secondary progressive multiple sclerosis (SPMS; EXPAND) and primary progressive multiple sclerosis (PPMS; INFORMS) using siponimod and fingolimod, respectively, as active compounds was performed. pNfL levels were quantified using a single molecule array (Homebrew Simoa) immunoassay from stored ethylenediaminetetraacetic acid (EDTA) plasma samples of all patients who consented for exploratory biomarker analysis in either study; pNfL levels were divided into high (≥30 pg/mL) and low (<30 pg/mL) at baseline. We investigated the association of pNfL levels with disability progression, cognitive decline, and brain atrophy and their sensitivity to indicate treatment response through clinical measures. Results We analyzed pNfL in 4,185 samples from 1,452 patients with SPMS and 1,172 samples from 378 patients with PPMS. Baseline pNfL levels were higher in SPMS (geomean 32.1 pg/mL) than in PPMS (22.0 pg/mL; p < 0.0001). In both studies, higher baseline pNfL levels were associated with older age, higher Expanded Disability Status Scale score, more Gd + lesions, and higher T2 lesion load (all p < 0.05). Independent of treatment, high vs low baseline pNfL levels were associated with significantly higher risks of confirmed 3-month (SPMS [32%], hazard ratio [95% CI] 1.32 [1.09–1.61]; PPMS [49%], 1.49 [1.05–2.12]) and 6-month disability progression (SPMS [26%], 1.26 [1.01–1.57]; PPMS [48%], 1.48 [1.01–2.17]), earlier wheelchair dependence (SPMS [50%], 1.50 [0.96–2.34]; PPMS [197%], 2.97 [1.44–6.10]), cognitive decline (SPMS [41%], 1.41 [1.09–1.84]), and higher rates of brain atrophy (mean change at month 24: SPMS, −0.92; PPMS, −1.39). Baseline pNfL levels were associated with future disability progression and the degree of brain atrophy regardless of presence or absence of acute disease activity (gadolinium-enhancing lesions or recent occurrence of relapses before baseline). pNfL levels were lower in patients treated with siponimod or fingolimod vs placebo-treated patients and higher in those having experienced disability progression. Discussion pNfL was associated with future clinical and radiologic disability progression features at the group level. pNfL was reduced by treatment and may be a meaningful outcome measure in PMS studies. Trial Registration Information EXPAND (ClinicalTrials.gov identifier: NCT01665144) and INFORMS (ClinicalTrials.gov identifier: NCT00731692)." @default.
• W4226153130 created "2022-05-05" @default.
• W4226153130 creator A5000363730 @default.
• W4226153130 creator A5038011784 @default.
• W4226153130 creator A5050196672 @default.
• W4226153130 creator A5054874316 @default.
• W4226153130 creator A5057032777 @default.
• W4226153130 creator A5069442374 @default.
• W4226153130 creator A5072651915 @default.
• W4226153130 creator A5076575343 @default.
• W4226153130 creator A5084571654 @default.
• W4226153130 date "2022-05-24" @default.
• W4226153130 modified "2023-10-14" @default.
• W4226153130 title "Blood Neurofilament Light in Progressive Multiple Sclerosis" @default.
• W4226153130 cites W1972013249 @default.
• W4226153130 cites W1977749401 @default.
• W4226153130 cites W2000900321 @default.
• W4226153130 cites W2105206040 @default.
• W4226153130 cites W2142577589 @default.
• W4226153130 cites W2162978315 @default.
• W4226153130 cites W2267348707 @default.
• W4226153130 cites W2340550513 @default.
• W4226153130 cites W2549644306 @default.
• W4226153130 cites W2600369824 @default.
• W4226153130 cites W2614808368 @default.
• W4226153130 cites W2677724969 @default.
• W4226153130 cites W2766371671 @default.
• W4226153130 cites W2767159844 @default.
• W4226153130 cites W2790816436 @default.
• W4226153130 cites W2791265204 @default.
• W4226153130 cites W2793526309 @default.
• W4226153130 cites W2803166003 @default.
• W4226153130 cites W2806791998 @default.
• W4226153130 cites W2898127494 @default.
• W4226153130 cites W2914396477 @default.
• W4226153130 cites W2946911440 @default.
• W4226153130 cites W2968485766 @default.
• W4226153130 cites W2978309950 @default.
• W4226153130 cites W2981120289 @default.
• W4226153130 cites W3026671074 @default.
• W4226153130 cites W3028430208 @default.
• W4226153130 cites W3042931334 @default.
• W4226153130 cites W3048381731 @default.
• W4226153130 cites W3094881665 @default.
• W4226153130 cites W3197437768 @default.
• W4226153130 cites W4226442578 @default.
• W4226153130 cites W4241890711 @default.
• W4226153130 cites W3001059714 @default.
• W4226153130 doi "https://doi.org/10.1212/wnl.0000000000200258" @default.
• W4226153130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35379762" @default.
• W4226153130 hasPublicationYear "2022" @default.
• W4226153130 type Work @default.
• W4226153130 citedByCount "16" @default.
• W4226153130 countsByYear W42261531302022 @default.
• W4226153130 countsByYear W42261531302023 @default.
• W4226153130 crossrefType "journal-article" @default.
• W4226153130 hasAuthorship W4226153130A5000363730 @default.
• W4226153130 hasAuthorship W4226153130A5038011784 @default.
• W4226153130 hasAuthorship W4226153130A5050196672 @default.
• W4226153130 hasAuthorship W4226153130A5054874316 @default.
• W4226153130 hasAuthorship W4226153130A5057032777 @default.
• W4226153130 hasAuthorship W4226153130A5069442374 @default.
• W4226153130 hasAuthorship W4226153130A5072651915 @default.
• W4226153130 hasAuthorship W4226153130A5076575343 @default.
• W4226153130 hasAuthorship W4226153130A5084571654 @default.
• W4226153130 hasBestOaLocation W42261531302 @default.
• W4226153130 hasConcept C126322002 @default.
• W4226153130 hasConcept C142724271 @default.
• W4226153130 hasConcept C143998085 @default.
• W4226153130 hasConcept C185592680 @default.
• W4226153130 hasConcept C203014093 @default.
• W4226153130 hasConcept C204787440 @default.
• W4226153130 hasConcept C207103383 @default.
• W4226153130 hasConcept C27081682 @default.
• W4226153130 hasConcept C2776036978 @default.
• W4226153130 hasConcept C2776819417 @default.
• W4226153130 hasConcept C2779134260 @default.
• W4226153130 hasConcept C2780596555 @default.
• W4226153130 hasConcept C2780640218 @default.
• W4226153130 hasConcept C2780892749 @default.
• W4226153130 hasConcept C2781028063 @default.
• W4226153130 hasConcept C2781172350 @default.
• W4226153130 hasConcept C2781197716 @default.
• W4226153130 hasConcept C44249647 @default.
• W4226153130 hasConcept C55493867 @default.
• W4226153130 hasConcept C67761136 @default.
• W4226153130 hasConcept C71924100 @default.
• W4226153130 hasConcept C90924648 @default.
• W4226153130 hasConceptScore W4226153130C126322002 @default.
• W4226153130 hasConceptScore W4226153130C142724271 @default.
• W4226153130 hasConceptScore W4226153130C143998085 @default.
• W4226153130 hasConceptScore W4226153130C185592680 @default.
• W4226153130 hasConceptScore W4226153130C203014093 @default.
• W4226153130 hasConceptScore W4226153130C204787440 @default.
• W4226153130 hasConceptScore W4226153130C207103383 @default.
• W4226153130 hasConceptScore W4226153130C27081682 @default.
• W4226153130 hasConceptScore W4226153130C2776036978 @default.
• W4226153130 hasConceptScore W4226153130C2776819417 @default.

• next